GDRX
GoodRx Holdings, Inc.
GDRX has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GDRX overall, supported by stronger fundamentals and stronger valuation.
GDRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
GDRX's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GDRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $3.51 | — |
| Cheap | 35x | $1.38 | -61% |
| Fair | 65x | $2.60 | -26% |
| Current | 88x | $3.51 | — |
| Expensive | 213x | $8.51 | +142% |
Historical ranges are pointers, not guarantees.
GDRX's PE is in its fair range at 88x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over GDRX in the historical PE scenario, which offers more potential upside but is not a forecast.
GDRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GDRX, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over GDRX on the outlook, with more favorable profitability expectations.
GDRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | +778% |
| Q2 2026 | $0.04 | -56% |
| Q1 2026 | $0.06 | -14% |
| Q4 2025 | $0.09 | +125% |
| Q3 2025 | $0.08 | +$0.11 |
| Q2 2025 | $0.09 | +$0.22 |
| Q1 2025 | $0.07 | +$0.08 |
| Q4 2024 | $0.04 | +$0.06 |
| Q3 2024 | -$0.03 | -200% |
GDRX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GDRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $200.4M | -1.3% |
| Q1 2026 | $194M | -4.4% |
| Q4 2025 | $194.8M | -1.9% |
| Q3 2025 | $196M | +0.4% |
| Q2 2025 | $203.1M | +1.2% |
| Q1 2025 | $203M | +2.6% |
| Q4 2024 | $198.6M | +1% |
| Q3 2024 | $195.3M | +8.5% |
GDRX's revenue grew through 2021 and has held roughly level since: $200M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -1.4 points |
| Q1 2026 | 7.2% | -4.3 points |
| Q4 2025 | 12% | +2.5 points |
| Q3 2025 | 7.5% | -3 points |
| Q2 2025 | 13% | +3.3 points |
| Q1 2025 | 12% | +7.8 points |
| Q4 2024 | 9.2% | +19 points |
| Q3 2024 | 10% | +32 points |
GDRX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GDRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GDRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $80.5M | +64% |
| Q1 2026 | $10.7M | +15% |
| Q4 2025 | $31.6M | -29% |
| Q3 2025 | $74.3M | -14% |
| Q2 2025 | $49.2M | +421% |
| Q1 2025 | $9.3M | -78% |
| Q4 2024 | $44.6M | +188% |
| Q3 2024 | $86.5M | +44% |
GDRX's free cash flow has been positive every quarter for six years: $197M over the past year, up 4% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GDRX on cash flow, with more consistent year-over-year improvement.
GDRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +6.6M shares |
| 1 year | -2.5% | -9.1M shares |
| 3 years | -16% | -66.3M shares |
| 5 years | -19% | -80.8M shares |
| Available history | -4% | -14.5M shares |
GDRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $2M |
| Q1 2026 | $12.6M |
| Q4 2025 | $9.4M |
| Q3 2025 | $61.1M |
| Q2 2025 | $46M |
| Q1 2025 | $99.9M |
| Q4 2024 | $188,000 |
| Q3 2024 | $5.4M |
GDRX spent $85M buying back its own shares over the past year, down 44% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GDRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 0.3x | Very low |
| Q3 2024 | 0.6x | Very low |
GDRX's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over GDRX on leverage, with a lower net debt burden relative to earnings.
GDRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 50.9 | Neutral |
GDRX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GDRX PE vs Healthcare Sector
| Metric | GDRX | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 63 | 33 | 30 pts above |
GDRX is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over GDRX on valuation relative to its sector.
GDRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.43 | 2.3% above |
| 20 week MA | $3.36 | 4.5% above |
| 50 week MA | $2.84 | 24% above |
| 100 week MA | $3.56 | 1.4% below |
| 200 week MA | $4.98 | 30% below |
GDRX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 30% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over GDRX on trend strength, trading above more of its moving averages.
GDRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.0 | $46.3 | -11% |
| 2021 | $46.3 | $33.6 | -28% |
| 2022 | $33.6 | $4.59 | -86% |
| 2023 | $4.59 | $6.70 | +46% |
| 2024 | $6.70 | $4.62 | -31% |
| 2025 | $4.62 | $2.75 | -40% |
| 2026 YTD | $2.75 | $3.51 | +28% |
GDRX has finished lower in five of the last six years. It's up 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GDRX on returns for 2026, with the stronger performance.